scholarly journals What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer?

2013 ◽  
Vol 20 (2) ◽  
Author(s):  
C. Cox ◽  
C.M. Holloway ◽  
A. Shaheta ◽  
S. Nofech-Mozes ◽  
F.C. Wright
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast

5063 POSTER Improvement of Neoadjuvant Therapy Response by Using 4FE100C Vs 6FE100C in Locally Advanced Breast Cancer

2011 ◽  
Vol 47 ◽  
pp. S349
Author(s):  
N. Ramirez-Torres ◽  
A. Perez-Puente ◽  
J. Asbun-Bojalil ◽  
E. Ruiz-Garcia ◽  
L.A. Valenzuela-Martinez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Therapy Response ◽  
Advanced Breast

Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 3049-3049 ◽  
Author(s):  
J. A. Lyons ◽  
P. Silverman ◽  
S. Remick ◽  
H. Chen ◽  
R. Leeming ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Phase Ii ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Advanced Breast ◽  
Colon Perforation ◽  
Randomized Phase Ii

3049 Background: Preclinical models of combination angiogenesis inhibitor bevacizumab (rhuMAbVEGF) and docetaxel demonstrate synergistic suppression of capillary vessel formation. Based upon these data, we developed a randomized phase II trial in order to evaluate the vascular effects on tumor regression with combination bevacizumab/docetaxel vs. docetaxel in the treatment of locally advanced breast cancer. Methods: 49 patients (pts) were randomized to receive neoadjuvant therapy with bevacizumab (10 mg/kg qowk) and docetaxel (two 8-week cycles of 35 mg/m2 weekly x 6 with a 2 wk break) (BD=24) or docetaxel (D=25) alone. Eligible pts had locally unresectable breast cancer with (n=6) or without distant metastasis (n=43); 16 patients presented with inflammatory breast cancer. Pts whose disease responded, sequentially underwent definitive surgery (4 weeks after BD or D), radiation, 4 cycles of conventional Adriamycin/cyclophosphamide, and tamoxifen or anastrazole (if ER/PR+). Results: Among the 49 pts: 7 clinical CRs, 32 PRs, 5 NR, and 5 PD. Of the 37 pts who underwent surgery: the median number of pathologically positive lymph nodes (LN) was 1 (BD=6, D=1; p=0.228); range 0–20; 43% were LN negative. Neoadjuvant treatment toxicity for both arms was acceptable with no significant differences between the two arms. Grade 4 toxicity included BD - new papillary thyroid cancer (1), neutropenia (1), hyperuricemia (1) and colon perforation (1); and D: - hyperglycemia (1) and hyperuricemia (1). 21 patients in each arm experienced a grade 3 toxicity. There were no episodes of uncontrolled hypertension, proteinuria, or thrombosis. Delayed wound healing (unable to start radiation w/in 6 weeks of surgery) occurred in 8 pts: BD=5; D=3 (p=0.691). Only 1 pt (D) experienced a change in LVEF by > 15% or below the institution’s lower limit of normal. Conclusions: Neoadjuvant therapy for locally advanced breast cancer using docetaxel with bevacizumab is well tolerated. Further studies are required to determine the added efficacy from bevacizumab. Correlative studies on impact of treatment on angiogenesis will be reported separately. (Sponsored by grants: K23CA 87725–01, M01 RR 00080, UO1 CA 62502, 5P30 CA43703-NCI/AVON, Aventis) No significant financial relationships to disclose.

Use of a portable gamma camera for guiding surgical treatment in locally advanced breast cancer in a post-neoadjuvant therapy setting

2014 ◽  
Vol 146 (2) ◽  
pp. 331-340 ◽  
Author(s):  
Laura Evangelista ◽  
Anna Rita Cervino ◽  
Riccardo Sanco ◽  
Michele Bignotto ◽  
Tania Saibene ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Advanced Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Gamma Camera ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Portable Gamma Camera
Sign in / Sign up

Export Citation Format

Share Document